Ciprofloxacin inhalation - Aradigm

Drug Profile

Ciprofloxacin inhalation - Aradigm

Alternative Names: ARD-1100; ARD-3100; ARD-3150; CFI; Ciprofloxacin AERx formulation - Aradigm; Ciprofloxacin inhalation modified-release - Aradigm Corporation; Ciprofloxacin inhalation sustained-release - Aradigm; Ciprofloxacin liposomal sustained-release - Aradigm; DRCFI; Dual Release Ciprofloxacin for Inhalation; ILCH; Inhaled liposomal ciprofloxacin hydrochloride; Linhaliq; Lipoquin; Pulmaquin

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aradigm Corporation
  • Developer Aradigm Corporation; Oregon State University
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Bronchiectasis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Bronchiectasis
  • Preclinical Acinetobacter infections; Anthrax; Mycobacterial infections; Pneumonic plague; Q fever; Tularaemia; Yersinia infections
  • Suspended Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 28 Jul 2017 Preregistration for non-cystic fibrosis Bronchiectasis in USA (Inhalation)
  • 28 Jul 2017 Efficacy and adverse events data from two phase III ORBIT-3 and ORBIT-4 trials in non-cystic fibrosis bronchiectasis released by Aradigm
  • 28 Mar 2017 Aradigm Corporation announces intention to submit NDA and MAA to the US FDA and the EMA for non-cystic fibrosis Bronchiectasis (9221261; 9213795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top